[en] Objective: To evaluate the clinical efficacy of CT-guided ¹²⁵I seed implantation in treating pelvic and retroperitoneal malignant tumors. Methods: CT-guided ¹²⁵I seed implantation was carried out in 23 patients with pelvic or retroperitoneal malignant tumors. Helical CT examination of abdomen or pelvic cavity was employed in all patients one week before the treatment, the image data were transferred to a computerized three-dimensional (3-D) tumor treatment planning system (TPS), the contour of target areas as well as the important organs around the tumor such as the bladder, bowel, large blood vessels, etc. were sketched. 3-D reconstruction of the target and the related profile was conducted. The radiation dose of target areas, the particle number and the particle space alignment were determined. The patients were followed up for 4 months to check the local treatment effect, the toxic and side effects of digestive tract and urinary system, the changes in pain and local tumor remission. Results: Of the 23 patients in this series, 16 had pain in the sacrococcygeal or lower back region before treatment. After treatment pain relief was obtained within 5-14 days, the effective rate was 87.5%, the short-term improvement for local pain was very remarkable. The 2-month and 4-month local control effective rates (CR+PR) were 47.8% (11/23) and 43.5% (10/23) respectively. During the follow-up period, no complications such as abdominal pain, pain in urination, radioactive enteritis, or bone marrow suppression, etc. occurred. Conclusion: This preliminary study shows that brachytherapy of CT-guided percutaneous ¹²⁵1 seed implantation is safe and effective for the treatment of pelvic and retroperitoneal malignant tumors. For the pelvic and retroperitoneal malignant tumors that are inoperable or postoperative recurrent, or that show poor response to pure radiotherapy and chemical therapy, this treatment is an effective and remedial therapeutic means, besides, it can effectively improve the quality of life of patients and improve the local control rate of tumor. (authors)

[en] Objective: To explore the short-term efficacy of argon-helium knife cryotherapy followed by chemotherapy in treating advanced non-small cell lung cancer (NSCLC) and to investigate its effect on the long-term survival. Methods: During the period from March 2005 to March 2008, a total of 61 patients with IIIb or IV stage NSCLC received argon-helium knife cryotherapy followed by chemotherapy (study group), and other 52 patients with IIIb or IV stage NSCLC were treated with chemotherapy only (control group). The clinical data were retrospectively analyzed. The pain was evaluated by numeric rating scale (NRS) and the quality of life (QOL) was assessed by functional assessment of cancer therapy-general (FACT-G) scale. The clinical effect was evaluated according to RECIST criteria for solid tumor, and the patient's survival time was recorded. Results: (1) Twenty-six patients had local pain before the treatment, and the pain was relieved in different degrees after cryotherapy. The QOL, including all respects of FACT-G, was significantly improved after cryotherapy in all 61 patients. (2) The remission rate of the study group and the control group was 34.4% and 15.4% respectively, the difference between the two groups was statistically significant (P < 0.05). (3) The median survival time of the study group and the control group was 12.9 months and 9.5 months respectively, and the one-year survival rate of the study group and the control group was 53.6% and 35.4% respectively. The differences between the two groups were statistically significant (P < 0.01). Conclusion: Argon-helium knife cryotherapy is a safe and effective local treatment for advanced NSCLC, which can quickly reduce the tumor load, relieve the pain and improve patient's quality of life. Cryotherapy with subsequent chemotherapy is superior to simple chemotherapy in improving the patient's survival rate. (authors)

[en] Objective: To investigate the safety and curative effect of CT-guided percutaneous cryoablation in treating recurrent tumors in pelvic cavity and retroperitoneal space. Methods: A total of 100 patients with recurrent tumors in pelvic cavity or retroperitoneal space were included in this study. CT-guided percutaneous cryoablation treatment was carried out in all patients. Results: (1) Of the 100 patients, complete cryoablation treatment was performed in 9 and palliative cryoablation treatment was adopted in 91. The following-up time ranged from 3 years to 11 years. The one-, 3- and 5-year survival rates were 87.0% (87/100), 17% (17/100) and 9% (9/100) respectively. The pain relief rate after cryoablation treatment was 84.0% (70/83). (2) Contrast-enhanced CT scan performed one month after cryoablation treatment showed that complete cryoablation was seen in 9 patients, presenting as no enhancement in the tumor frozen area on CT image; palliative cryoablation was seen in 91 patients, the ablation extent ≥ 90% was obtained in 48 patients, the ablation extent of 80-90% in 25 patients, the ablation extent of 70-80% in 12 patients, the ablation extent of 60-70% in 4 patients, and the ablation extent < 60% in 3 patients. (3) Postoperative complications included local infection (n = 3), which was cured after anti-infective therapy; intestinal fistula at upper rectum (n = 1), which was gradually healed after enterostomy; transient dysuresia (n = 5), which was recovered through retention catheterization for 3-5 days; fever lasting 3-5 days; and skin frostbite (n = 3), which was cured after symptomatic treatment. Conclusion: For the treatment of recurrent tumors in pelvic cavity and retroperitoneal space, CT-guided percutaneous cryoablation is quite safe. Complete cryoablation is very helpful for improving local tumor control and prolonging survival time. (authors)

[en] Objective: To explore the short-term efficacy and safety of domestic cryoablation targeted knife in the treatment of stage I lung cancers. Methods: A total of 24 patients with stage I lung cancer, who underwent CT-guided cryoablation with domestic targeted knife during the period from January 1, 2016 to June 30, 2018, were collected. The parameters of frozen ice spheres obtained from intraoperative CT scan were used to assess the complete ablation rate, the short-term local recurrence rate, the surgery-related complications and the one-year survival rate. Results: The complete ablation rate was 100%. During the follow-up period lasting for 12 months, all 24 patients survived, 3 patients had a small amount of pneumothorax after cryoablation. No hemoptysis, serious complications or death occurred. Conclusion: For the treatment of stage I lung cancers, cryoablation with domestic targeted knife is safe and effective, and the tumor body can be effectively inactivated. 28: 958-961). (authors)